$38,008,679

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactiveONGOING · MOD OF 2021 CONTRACT

WORK BEGAN2021-11-29·LATEST ACTION2026-03-11·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50122C00008_7505_-NONE-_-NONE-

Award description

HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES.

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Develop high-throughput immunoassay to detect neutralizing antibodies against SARS-CoV-2 variants in human serum samples.

Sub-sectors

vaccine-developmentdiagnostic-assayscovid-19-response

Why this matters

Enables rapid assessment of vaccine efficacy and population immunity levels across COVID-19 variants, critical for pandemic preparedness.

Supply-chain signal

Signals continued demand for diagnostic manufacturing capacity and reagent suppliers supporting large-scale serology testing infrastructure.

U.S.–China competition angle

Demonstrates U.S. investment in domestic diagnostic capabilities to reduce reliance on foreign testing platforms during future pandemics.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002235.

Period of performance

Start

2021-11-29

End

2029-09-30

Status

activein 1230 days

Recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00008_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.